United Therapeutics (UTHR) is a publicly traded Healthcare sector company. As of July 10, 2026, UTHR trades at $543.62 with a market cap of $23.53B and a P/E ratio of 18.75. UTHR moved -1.76% today. Year to date, UTHR is +13.39%; over the trailing twelve months it is +83.82%. Its 52-week range spans $266.98 to $609.35. Analyst consensus is strong buy with an average price target of $676.00. Rallies surfaces UTHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for UTHR, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $543.62 |
| Market Cap | $23.53B |
| P/E Ratio | 18.75 |
| EPS | $29.27 |
| Dividend Yield | 0.00% |
| 52-Week High | $609.35 |
| 52-Week Low | $266.98 |
| Volume | 91.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.17B |
| Net Income | $1.29B |
| Gross Margin | 86.58% |
9 analysts cover UTHR: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $676.00.